BlackRock Amends Amgen Stake: Passive Investment Update

TL;DR

**BlackRock updated its Amgen stake, signaling a passive investment change.**

AI Summary

BlackRock Inc. filed an amended Schedule 13G/A on January 25, 2024, indicating a change in their ownership of Amgen Inc. common stock as of December 31, 2023. This filing, Amendment No. 14, updates their previous disclosures regarding their passive investment in the biotechnology giant. This matters to investors because BlackRock is a major institutional investor, and changes in their holdings can signal shifts in their confidence or investment strategy regarding Amgen, potentially influencing other investors.

Why It Matters

This filing shows BlackRock's updated passive ownership in Amgen, providing transparency on a major institutional investor's position, which can influence market sentiment.

Risk Assessment

Risk Level: low — This is a routine update from a passive institutional investor and does not indicate any immediate significant risk or opportunity.

Analyst Insight

Investors should note that BlackRock, a major institutional investor, has updated its passive stake in Amgen. While this specific filing doesn't detail the exact change in share count or percentage, it signals a routine update to their investment position. Smart investors would look for the full details within the filing to understand if BlackRock increased or decreased its stake, and then consider this alongside Amgen's recent performance and future outlook.

Key Players & Entities

• BlackRock Inc. (company) — the reporting person filing the SC 13G/A
• Amgen Inc. (company) — the subject company whose securities are being reported
• December 31, 2023 (date) — the date of the event requiring the filing
• January 25, 2024 (date) — the filing date of the SC 13G/A
• Amendment No. 14 (number) — the specific amendment number of the filing

FAQ

From the Filing

0001086364-24-003323.txt : 20240125 0001086364-24-003323.hdr.sgml : 20240125 20240125134856 ACCESSION NUMBER: 0001086364-24-003323 CONFORMED SUBMISSION TYPE: SC 13G/A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20240125 DATE AS OF CHANGE: 20240125 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: AMGEN INC CENTRAL INDEX KEY: 0000318154 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 953540776 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-34640 FILM NUMBER: 24561119 BUSINESS ADDRESS: STREET 1: ONE AMGEN CENTER DRIVE CITY: THOUSAND OAKS STATE: CA ZIP: 91320 BUSINESS PHONE: (805)447-1000 MAIL ADDRESS: STREET 1: ONE AMGEN CENTER DRIVE CITY: THOUSAND OAKS STATE: CA ZIP: 91320 FORMER COMPANY: FORMER CONFORMED NAME: AMGEN DATE OF NAME CHANGE: 19870305 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: BlackRock Inc. CENTRAL INDEX KEY: 0001364742 STANDARD INDUSTRIAL CLASSIFICATION: SECURITY BROKERS, DEALERS & FLOTATION COMPANIES [6211] ORGANIZATION NAME: 02 Finance IRS NUMBER: 320174431 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G/A BUSINESS ADDRESS: STREET 1: 50 HUDSON YARDS CITY: NEW YORK STATE: NY ZIP: 10001 BUSINESS PHONE: 212-810-5300 MAIL ADDRESS: STREET 1: 50 HUDSON YARDS CITY: NEW YORK STATE: NY ZIP: 10001 FORMER COMPANY: FORMER CONFORMED NAME: BlackRock, Inc. DATE OF NAME CHANGE: 20060929 FORMER COMPANY: FORMER CONFORMED NAME: New BlackRock, Inc. DATE OF NAME CHANGE: 20060601 SC 13G/A 1 us0311621009_012524.txt us0311621009_012524.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 14) AMGEN INC -------------------------------------------------------- (Name of Issuer) Common Stock -------------------------------------------------------- (Title of Class of Securities) 031162100 -------------------------------------------------------- (CUSIP Number) December 31, 2023 -------------------------------------------------------- (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [X] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). CUSIP No. 031162100 (1)Names of reporting persons. BlackRock, Inc. (2) Check the appropriate box if a member of a group (a) [ ] (b) [X] (3) SEC use only (4) Citizenship or place of organization Delaware Number of shares beneficially owned by each reporting person with: (5) Sole voting power 43538050 (6) Shared voting power 0 (7) Sole dispositive power 47811356 (8) Shared dispositive power 0 (9) Aggregate amount beneficially owned by each reporting person 47811356 (10) Check if the aggregate amount in Row (9) excludes certain shares (11) Percent of class represented by amount in Row 9 8.9% (12) Type of reporting person HC Item 1. Item 1(a) Name of issuer: ----------------------------------------------------------------------- AMGEN INC Item 1(b) Address of issuer's principal executive offices: ----------------------------------------------------------------------- ONE AMGEN CENTER DRIVE THOUSAND OAKS CA 91320 Item 2. 2(a) Name of person filing: ---------------------------------------------------------------------- BlackRock, Inc. 2(b) Address or pr